Search over 3,000 reports

    Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2027

    Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2027
    Date: Aug, 2017
    Type: Pharmaceutical Industry Report
    Pages: 70
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0019
    DelveInsight's "Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Nonalcoholic Steatohepatitis (NASH) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Nonalcoholic Steatohepatitis (NASH) . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Nonalcoholic Steatohepatitis (NASH) for 7 major markets.

    The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Nonalcoholic Steatohepatitis (NASH) market, as well as treatment algorithm, current treatments & advancements are included. The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Nonalcoholic Steatohepatitis (NASH) , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

    According to DelveInsight, the forecasted patient population of Nonalcoholic Steatohepatitis (NASH) for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Nonalcoholic Steatohepatitis (NASH) 7MM market size is estimated to be USD XX by 2025. The DelveInsight Report will help in enhanced understanding of the Nonalcoholic Steatohepatitis (NASH) market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

    Key Coverage

    • Understanding historical and forecasted epidemiological data for Nonalcoholic Steatohepatitis (NASH) covering 7MM from 2015-2025.
    • Segment level epidemiology and market split for Nonalcoholic Steatohepatitis (NASH) .
    • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Nonalcoholic Steatohepatitis (NASH) .
    • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Nonalcoholic Steatohepatitis (NASH) market trends.
    • Thorough market distribution based on market share for Nonalcoholic Steatohepatitis (NASH) .

    Reasons to buy

    • The report will help in developing business strategies by understanding trends shaping and driving the Nonalcoholic Steatohepatitis (NASH) market.
    • To understand the future market competition in the Nonalcoholic Steatohepatitis (NASH) market and Insightful review of the key market drivers and barriers.
    • Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
    • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
    1. Report Introduction
    2. Nonalcoholic Steatohepatitis (NASH) Market Overview at a Glance
    2.1. Total Market Share Distribution of Nonalcoholic Steatohepatitis (NASH) for 7 MM in 2016
    2.2. Total Market Share Distribution of Nonalcoholic Steatohepatitis (NASH) for 7 MM in 2025
    3. Nonalcoholic Steatohepatitis (NASH)
    3.1.1. Overview
    3.1.2. Symptoms
    3.1.3. Pathophysiology
    3.1.4. Staging
    3.1.5. Diagnosis
    3.1.6. Treatment
    4. Epidemiology and Patient Population
    4.1.1. United States
    4.1.1.1. Diagnosed Cases of Nonalcoholic Steatohepatitis (NASH) in United States
    4.1.2. Germany
    4.1.2.1. Diagnosed Cases of Nonalcoholic Steatohepatitis (NASH) in Germany
    4.1.3. France
    4.1.3.1. Diagnosed Cases of Nonalcoholic Steatohepatitis (NASH) in France
    4.1.4. Italy
    4.1.4.1. Diagnosed Cases of Nonalcoholic Steatohepatitis (NASH) in Italy
    4.1.5. Spain
    4.1.5.1. Diagnosed Cases of Nonalcoholic Steatohepatitis (NASH) in Spain
    4.1.6. United Kingdom
    4.1.6.1. Diagnosed Cases of Nonalcoholic Steatohepatitis (NASH) in United Kingdom
    5. Treatment Algorithm
    5.1.1. Treatment Guidelines/Practices
    6. Marketed Drugs for Nonalcoholic Steatohepatitis (NASH)
    6.1. Drug 1: Company A
    6.1.1. Drug Description
    6.1.2. Mechanism of Action
    6.1.3. Regulatory Milestones
    6.1.4. Advantages & Disadvantages
    6.1.5. Safety and Efficacy
    6.1.6. Product Profile
    6.1.7. Patent Status
    6.2. Drug 2: Company B
    6.2.1. Drug Description
    6.2.2. Mechanism of Action
    6.2.3. Regulatory Milestones
    6.2.4. Advantages & Disadvantages
    6.2.5. Safety and Efficacy
    6.2.6. Product Profile
    6.2.7. Patent Status
    7. Emerging Therapies
    7.1. Drug 3: Company C
    7.1.1. Description
    7.1.2. Regulatory Milestones
    7.1.3. Advantages & Disadvantages
    7.1.4. Product Profile
    7.1.5. Launch Date
    7.1.6. Clinical Development
    7.1.7. Clinical Pipeline Activity
    7.1.8. Ongoing Trials Information
    7.1.9. Clinical Trial by Phase
    7.2. Drug 4: Company B
    7.2.1. Description
    7.2.2. Regulatory Milestones
    7.2.3. Advantages & Disadvantages
    7.2.4. Product Profile
    7.2.5. Launch Date
    7.2.6. Clinical Development
    7.2.7. Clinical Pipeline Activity
    7.2.8. Ongoing Trials Information
    7.2.9. Clinical Trial by Phase
    8. Overview of Total Nonalcoholic Steatohepatitis (NASH) Market (2016 & 2025)
    9. Nonalcoholic Steatohepatitis (NASH) : Country-Wise Market Analysis
    9.1. United States
    9.1.1. Historical Market Size (2015-2016)
    9.1.2. Forecasted Market Size (2017-2025)
    9.2. Germany Market Size
    9.2.1. Historical Market Size (2015-2016)
    9.2.2. Forecasted Market Size (2017-2025)
    9.3. France Market Size
    9.3.1. Historical Market Size (2015-2016)
    9.3.2. Forecasted Market Size (2017-2025)
    9.4. United Kingdom Market Size
    9.4.1. Historical Market Size (2015-2016)
    9.4.2. Forecasted Market Size (2017-2025)
    9.5. Spain Market Size
    9.5.1. Historical Market Size (2015-2016)
    9.5.2. Forecasted Market Size (2017-2025)
    9.6. Italy Market Size
    9.6.1. Historical Market Size (2015-2016)
    9.6.2. Forecasted Market Size (2017-2025)
    9.7. Japan Market Size
    9.7.1. Historical Market Size (2015-2016)
    9.7.2. Forecasted Market Size (2017-2025)
    10. Market Drivers
    11. Market Restraints
    12. Appendix
    13. Report Methodology
    14. Consulting Services
    15. Disclaimer
    16. About DelveInsight
    Table 1: Diagnosed Cases NASH in United States (2015-2027)
    Table 2: Diagnosed Cases NASH in Germany (2015-2027)
    Table 3: Diagnosed Cases NASH in France (2015-2027)
    Table 4: Diagnosed Cases NASH in United Kingdom (2015-2027)
    Table 5: Diagnosed Cases NASH in Spain (2015-2027)
    Table 6: Diagnosed Cases NASH in Italy (2015-2027)
    Table 7: Diagnosed Cases NASH in Japan (2015-2027)
    Table 8: List of Marketed Drugs for NASH
    Table 9: List of Pipeline Phase III Drugs for NASH
    Table 10: Drug 1, Clinical Trials by Zone, 2017
    Table 11: Clinical Trials by Trial status, 2017
    Table 12: Drug 2, Clinical Trials by Zone, 2017
    Table 13: Clinical Trials by Trial status, 2017
    Table 14: Drug 3, Clinical Trials by Zone, 2017
    Table 15: Clinical Trials by Trial status, 2017
    Table 16: United States Market Size of NASH in USD, Million (2015-2027)
    Table 17: Germany Market Size of NASH in USD, Million (2015-2027)
    Table 18: France Market Size of NASH in USD, Million (2015-2027)
    Table 19: United Kingdom Market Size of NASH in USD, Million (2015-2027)
    Table 20: Spain Market Size of NASH in USD, Million (2015-2027)
    Table 21: Italy Market Size of NASH in USD, Million (2015-2027)
    Table 22: Japan Market Size of NASH in USD, Million (2015-2027)

    Figure 1: Diagnosed Cases NASH in United States (2015-2027)
    Figure 2: Diagnosed Cases NASH in Germany (2015-2027)
    Figure 3: Diagnosed Cases NASH in France (2015-2027)
    Figure 4: Diagnosed Cases NASH in United Kingdom (2015-2027)
    Figure 5: Diagnosed Cases NASH in Spain (2015-2027)
    Figure 6: Diagnosed Cases NASH in Italy (2015-2027)
    Figure 7: Diagnosed Cases NASH in Japan (2015-2027)
    Figure 8: List of Marketed Drugs for NASH
    Figure 9: List of Pipeline Phase III Drugs for NASH
    Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
    Figure 11: Clinical Trials by Trial status, 2017
    Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
    Figure 13: Clinical Trials by Trial status, 2017
    Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
    Figure 15: Clinical Trials by Trial status, 2017
    Figure 16: United States Market Size of NASH in USD, Million (2015-2027)
    Figure 17: Germany Market Size of NASH in USD, Million (2015-2027)
    Figure 18: France Market Size of NASH in USD, Million (2015-2027)
    Figure 19: United Kingdom Market Size of NASH in USD, Million (2015-2027)
    Figure 20: Spain Market Size of NASH in USD, Million (2015-2027)
    Figure 21: Italy Market Size of NASH in USD, Million (2015-2027)
    Figure 22: Japan Market Size of NASH in USD, Million (2015-2027)

    Nonalcoholic Steatohepatitis (NASH) Market (7MM)

    Nonalcoholic Steatohepatitis (NASH) Market forecasting

    Nonalcoholic Steatohepatitis (NASH) Sales forecasting

    Nonalcoholic Steatohepatitis (NASH) Market segments

    Nonalcoholic Steatohepatitis (NASH) Epidemiology

    Nonalcoholic Steatohepatitis (NASH) Pipeline products and technologies

    Nonalcoholic Steatohepatitis (NASH) Competitive landscape

    Nonalcoholic Steatohepatitis (NASH) SWOT analysis

    Nonalcoholic Steatohepatitis (NASH) Market Driver's and barriers

    Nonalcoholic Steatohepatitis (NASH) Key Companies and Funding



    • Single User License
      $5,750.00
    • Site License
      $11,500.00
    • Global License
      $17,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap